19:58 , Sep 21, 2017 |  BC Innovations  |  Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
13:23 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Blindness Mouse studies suggest inhibiting MEF2D could help treat light-induced retinal degeneration. In retinal tissue samples from a mouse model of the disease, the MEF2D inhibitor tool compound carnosic acid decreased cell death and...
20:01 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL); B cell lymphoma Patient sample, cell culture and mouse studies suggest HDAC inhibitors could help treat patients with B cell precursor ALL expressing gene fusions involving MEF2D . Levels of...
07:00 , Sep 6, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Myocyte enhancer factor 2D (MEF2D) Mouse studies suggest activating the transcription factor MEF2D with the dimeric acetylcholinesterase (AChE) inhibitor bis(3)-cognitin (B3C) could...